TY - JOUR AU - Addeo, Alfredo AU - Weiss, Glen J. PY - 2019 TI - Measuring tumor mutation burden in cell-free DNA: advantages and limits JF - Translational Lung Cancer Research; Vol 8, No 4 (August 31, 2019): Translational Lung Cancer Research Y2 - 2019 KW - N2 - The treatment for advanced non-small cell lung cancer (NSCLC) has changed rapidly over the last several years. There are now several commercially available checkpoint inhibitors (CPI) targeting the programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) pathway. These CPIs have been shown to confer a significant overall survival (OS) benefit in first- and second-line therapy for unresectable/metastatic NSCLC (1-5). While the use of CPI in the clinic is prevalent, the determinants of those most likely to benefit remains imprecise. UR - https://tlcr.amegroups.org/article/view/27724